/PRNewswire/ Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the.
STOCKHOLM, April 30, 2024 /PRNewswire/ — Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the fact that the median time to progression with fostrox + Lenvima increased to 7 months. January – March Financial summary for the quarter Net turnover amounted to […]
The Nomination Committee s in Medivir AB proposal for the 2024 annual general meeting In accordance with the principles decided by the 2023 annual general.
Noce of Annual General Meeng of Medivir AB The shareholders of Medivir AB , reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are.
Orwell Prize nominated writer on decolonising medicine, being inspired by her father and her experiences working as a sexual and reproductive health registrar in the NHS